1. Home
  2. TGTX vs SPSC Comparison

TGTX vs SPSC Comparison

Compare TGTX & SPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TGTX
  • SPSC
  • Stock Information
  • Founded
  • TGTX 1993
  • SPSC 1987
  • Country
  • TGTX United States
  • SPSC United States
  • Employees
  • TGTX N/A
  • SPSC N/A
  • Industry
  • TGTX Biotechnology: Pharmaceutical Preparations
  • SPSC EDP Services
  • Sector
  • TGTX Health Care
  • SPSC Technology
  • Exchange
  • TGTX Nasdaq
  • SPSC Nasdaq
  • Market Cap
  • TGTX 5.5B
  • SPSC 5.1B
  • IPO Year
  • TGTX 1995
  • SPSC 2010
  • Fundamental
  • Price
  • TGTX $33.65
  • SPSC $112.09
  • Analyst Decision
  • TGTX Strong Buy
  • SPSC Buy
  • Analyst Count
  • TGTX 6
  • SPSC 11
  • Target Price
  • TGTX $47.50
  • SPSC $156.18
  • AVG Volume (30 Days)
  • TGTX 1.5M
  • SPSC 350.9K
  • Earning Date
  • TGTX 11-04-2025
  • SPSC 10-30-2025
  • Dividend Yield
  • TGTX N/A
  • SPSC N/A
  • EPS Growth
  • TGTX N/A
  • SPSC 13.55
  • EPS
  • TGTX 0.36
  • SPSC 2.18
  • Revenue
  • TGTX $454,069,000.00
  • SPSC $703,542,000.00
  • Revenue This Year
  • TGTX $82.13
  • SPSC $21.81
  • Revenue Next Year
  • TGTX $49.01
  • SPSC $9.21
  • P/E Ratio
  • TGTX $92.64
  • SPSC $51.61
  • Revenue Growth
  • TGTX 30.96
  • SPSC 20.51
  • 52 Week Low
  • TGTX $22.61
  • SPSC $102.05
  • 52 Week High
  • TGTX $46.48
  • SPSC $201.06
  • Technical
  • Relative Strength Index (RSI)
  • TGTX 48.14
  • SPSC 55.94
  • Support Level
  • TGTX $34.01
  • SPSC $106.57
  • Resistance Level
  • TGTX $35.52
  • SPSC $113.71
  • Average True Range (ATR)
  • TGTX 1.28
  • SPSC 3.03
  • MACD
  • TGTX -0.24
  • SPSC 0.86
  • Stochastic Oscillator
  • TGTX 16.02
  • SPSC 81.80

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

About SPSC SPS Commerce Inc.

SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. Its products are; Fulfillment, Analytics, and Other products like Assortment and Community also it provides one-time services such as professional services and testing and certification. The group derives revenue from subscription-based recurring revenue services.

Share on Social Networks: